MCID: UTR043
MIFTS: 44

Uterine Sarcoma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Uterine Sarcoma

Aliases & Descriptions for Uterine Sarcoma:

Name: Uterine Sarcoma 50 52
Uterine Corpus Sarcoma 69
Sarcoma of the Uterus 50

Classifications:



Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to adenosarcoma and sarcoma. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MicroRNAs in cancer. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotypes are Decreased viability and cardiovascular system

Wikipedia : 71 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
id Related Disease Score Top Affiliating Genes
1 adenosarcoma 28.8 DES KIT MB MDM2 PDGFRB WT1
2 sarcoma 10.8
3 choriocarcinoma 10.3 KIT WT1
4 kahrizi syndrome 10.3 KIT PDGFRB WT1
5 hyperandrogenism due to cortisone reductase deficiency 10.3 KIT PDGFRB WT1
6 diffuse glomerulonephritis 10.2 KIT SMARCB1 WT1
7 glycerol kinase deficiency, adult form 10.2 CYP19A1 ESR1 KIT
8 carbon monoxide-induced parkinsonism 10.2 DES KIT
9 appendix leiomyoma 10.2 ESR1 MB
10 familial hyperaldosteronism 10.2 KIT MVP WT1
11 peroxisome biogenesis disorder 7a 10.2 ABCB1 KIT PDGFRB WT1
12 atypical lipomatous tumor 10.1 ESR1 KIT
13 gangliosidosis gm1 10.1 DES ESR1 KIT
14 nodular basal cell carcinoma 10.1 ABCB1 ABCC1
15 plexopathy 10.1 MB SMARCB1 WT1
16 lice infestation 10.1 KIT MB SMARCB1
17 lung benign neoplasm 10.1 DES SMARCB1 WT1
18 small intestinal sarcoma 10.1 KIT MDM2 WT1
19 microsporidiosis 10.1 CDK2 KIT MB
20 neurofibroma 10.1 MB SMARCB1 WT1
21 c-p angle neurinoma 10.1 DES KIT SMARCB1
22 uterine inversion 10.1
23 testis sarcoma 10.1 DES KIT
24 multifocal osteogenic sarcoma 10.1 KIT MDM2 PDGFRB
25 hemophagocytic lymphohistiocytosis 10.1 ABCB1 DCK KIT PDGFRB WT1
26 mixed type rhabdomyosarcoma 10.1 DES MB
27 marfanoid hypermobility syndrome 10.1 DES KIT
28 gestational choriocarcinoma 10.1 KIT MDM2 WT1
29 breast angiomatosis 10.1 ESR1 MME
30 leiomyoma 10.1
31 glaucoma iridogoniodysgenesia 10.0 DES MB
32 verruciform xanthoma of skin 10.0 DES MB
33 t-cell childhood lymphoblastic lymphoma 10.0 DES MB PDGFRB
34 spindle cell rhabdomyosarcoma 10.0 DES MB WT1
35 hormone producing pituitary cancer 10.0 KIT MDM2 SMARCB1 WT1
36 intrahepatic bile duct cystadenoma 10.0 DES MB
37 endodermal sinus tumor 10.0 KIT MB MDM2
38 phosphoserine phosphatase deficiency 10.0 ABCB1 ABCC1 MVP WT1
39 enchondromatosis dwarfism deafness 10.0 DES KIT MDM2
40 diarrhea, chronic, with villous atrophy 10.0 DES KIT MDM2
41 childhood medulloblastoma 10.0 DES MB SMARCB1
42 breast duct papilloma 10.0 CYP19A1 ESR1 MME
43 endocrine organ benign neoplasm 10.0 KIT MME SMARCB1
44 pulmonary immaturity 10.0 KIT MB MDM2
45 thyroid carcinoma, papillary, with papillary renal neoplasia 10.0 KIT MME WT1
46 osteomyelitis 10.0 DES MDM2
47 cecum adenoma 9.9 DES KIT MDM2
48 thoracic outlet syndrome 9.9 CDK2 MDM2 SMARCB1
49 sebaceous adenoma 9.9 DES KIT MME
50 amyloidosis, hereditary, transthyretin-related 9.9 DES KIT MDM2

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.91 DCK
2 Decreased viability GR00221-A-1 9.91 SMARCB1 DCK ESR1 KIT PDGFRB
3 Decreased viability GR00221-A-2 9.91 SMARCB1 DCK ESR1
4 Decreased viability GR00221-A-3 9.91 PDGFRB SMARCB1
5 Decreased viability GR00221-A-4 9.91 PDGFRB DCK ESR1
6 Decreased viability GR00240-S-1 9.91 DCK
7 Decreased viability GR00301-A 9.91 KIT
8 Decreased viability GR00342-S-1 9.91 PDGFRB
9 Decreased viability GR00381-A-1 9.91 SMARCB1
10 Increased HPV16-GFP infection GR00350-A 8.92 PGRMC1 ABCC1 DCK DES

MGI Mouse Phenotypes related to Uterine Sarcoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 MB PDGFRB MCAM MDM2 KIT WT1
2 cellular MP:0005384 10.25 MB PDGFRB MDM2 KIT SMARCB1 WT1
3 hematopoietic system MP:0005397 10.25 MB PDGFRB MCAM MDM2 KIT WT1
4 homeostasis/metabolism MP:0005376 10.25 MME MB PDGFRB MCAM MDM2 KIT
5 behavior/neurological MP:0005386 10.24 KIT MCAM ESR1 MDM2 SMARCB1 PDGFRB
6 immune system MP:0005387 10.18 MME PDGFRB MCAM MDM2 KIT WT1
7 endocrine/exocrine gland MP:0005379 10.11 PDGFRB MDM2 KIT WT1 CDK2 ESR1
8 embryo MP:0005380 10.08 MB PDGFRB MDM2 KIT SMARCB1 WT1
9 digestive/alimentary MP:0005381 10.04 PDGFRB MDM2 KIT SMARCB1 ESR1 CYP19A1
10 liver/biliary system MP:0005370 9.97 MME MDM2 KIT SMARCB1 WT1 CDK2
11 muscle MP:0005369 9.96 MB PDGFRB MDM2 KIT WT1 SMARCB1
12 neoplasm MP:0002006 9.63 KIT ESR1 MDM2 SMARCB1 WT1 CDK2
13 normal MP:0002873 9.56 KIT MVP ESR1 MDM2 WT1 PDGFRB
14 reproductive system MP:0005389 9.28 PDGFRB MDM2 KIT SMARCB1 WT1 CDK2

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
8
Morphine Approved, Investigational Phase 3 57-27-2 5288826
9
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
10
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
11
Mesna Approved Phase 3,Phase 2 3375-50-6 598
12
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
15
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
16
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
19
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
20
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
24 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
25 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Isophosphamide mustard Phase 3,Phase 2,Phase 1
30 Liver Extracts Phase 3,Phase 1,Phase 2
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Antiviral Agents Phase 3,Phase 2,Phase 1
38 pancreatic polypeptide Phase 3
39 Epoetin alfa Phase 3 113427-24-0
40 Analgesics Phase 3,Phase 1
41 Mitogens Phase 3,Phase 2,Phase 1
42 Adjuvants, Anesthesia Phase 3
43 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
44 Narcotics Phase 3
45 Gastrointestinal Agents Phase 3,Phase 2
46 Analgesics, Opioid Phase 3
47 Anesthetics Phase 3,Phase 2
48 Anesthetics, General Phase 3
49 Anesthetics, Intravenous Phase 3
50 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 185)
id Name Status NCT ID Phase
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
3 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
4 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
5 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
6 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3
7 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3
8 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Completed NCT01012297 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
11 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
12 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
13 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
14 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3
15 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Recruiting NCT01533207 Phase 3
16 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3
17 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3
18 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
19 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2
20 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
22 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
23 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
24 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2
25 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2
26 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2
27 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2
28 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
29 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2
30 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2
31 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2
32 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2
33 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2
34 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2
35 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2
36 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2
37 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2
38 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2
39 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2
40 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
41 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
42 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
43 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2
44 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
45 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
46 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2
47 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2
48 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2
49 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
50 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

39
Uterus, Smooth Muscle, Breast, Bone, Endothelial, Placenta, Colon

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 278)
id Title Authors Year
1
Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis. ( 27668397 )
2017
2
Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand. ( 27221849 )
2016
3
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. ( 27208537 )
2016
4
A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. ( 26828206 )
2016
5
Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation. ( 26807642 )
2016
6
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. ( 26855091 )
2016
7
A uterus soaked in blood with low haemoglobin in a case of unrecognized uterine sarcoma. ( 27048123 )
2016
8
Uterine sarcoma vs adenocarcinoma: can MRI distinguish between them? ( 26617259 )
2016
9
Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. ( 26646120 )
2016
10
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. ( 27012429 )
2016
11
Laparoscopic surgery on broken points for uterine sarcoma in the early stage decrease prognosis. ( 27503773 )
2016
12
Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma. ( 26893869 )
2016
13
Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease. ( 27553655 )
2016
14
Morcellation of undiagnosed uterine sarcoma: A critical review. ( 26672915 )
2016
15
Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. ( 27177280 )
2016
16
Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review. ( 27590366 )
2016
17
Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. ( 27590365 )
2016
18
Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. ( 27751406 )
2016
19
Correction: A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. ( 27078148 )
2016
20
Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids. ( 26645385 )
2016
21
Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. ( 26695124 )
2016
22
Erratum to: PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. ( 25687505 )
2015
23
Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. ( 26253281 )
2015
24
Incidence of Uterine Sarcoma in 1432 Consecutive Minimally Invasive Hysterectomies. ( 27679214 )
2015
25
Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. ( 26711836 )
2015
26
ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line. ( 25603048 )
2015
27
Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. ( 25765878 )
2015
28
Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG. ( 25797958 )
2015
29
A Comparative Study of the Methods of Diagnosis and Outcomes of Different Uterine Sarcoma Types. ( 27679119 )
2015
30
Laparoscopic hysterectomy with a handheld robotic device in a case of uterine sarcoma. ( 25675928 )
2015
31
Outcome analysis in patients with uterine sarcoma. ( 25874175 )
2015
32
Population-based estimates of the prevalence of uterine sarcoma among patients with leiomyomata undergoing surgical treatment. ( 25650751 )
2015
33
CD146 as an adverse prognostic factor in uterine sarcoma. ( 26293576 )
2015
34
Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? ( 27679281 )
2015
35
Uterine Sarcoma: The Indian Scenario. ( 27217670 )
2015
36
Uterine Sarcoma, Version 1.2016. ( 26553763 )
2015
37
Clinical characteristics and management experience of unexpected uterine sarcoma after myomectomy. ( 26117552 )
2015
38
Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma. ( 25550573 )
2015
39
Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases. ( 26508879 )
2015
40
PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. ( 25596698 )
2015
41
Incidence of Tissue Morcellation During Surgery for Uterine Sarcoma at a Canadian Academic Centre. ( 26168102 )
2015
42
Pelvic splenosis misdiagnosed as a uterine sarcoma. ( 26076145 )
2015
43
Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms. ( 26026076 )
2015
44
ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY. ( 26122223 )
2015
45
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. ( 27679197 )
2015
46
Establishment and characterization of a novel orthotopic mouse model for human uterine sarcoma with different metastatic potentials. ( 26164209 )
2015
47
A Multi-Center Retrospective Review of Clinical Characteristics of Uterine Sarcoma. ( 27679381 )
2015
48
Undifferentiated uterine sarcoma: a rare, not well known and aggressive disease: report of 13 cases. ( 24958349 )
2014
49
Current and future options in the management and treatment of uterine sarcoma. ( 24381658 )
2014
50
Uterine sarcoma. Clinico-pathological characteristics and outcome. ( 25316466 )
2014

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

GO Terms for Uterine Sarcoma

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.58 ESR1 KIT SMARCB1
2 androgen metabolic process GO:0008209 9.46 CYP19A1 ESR1
3 uterus development GO:0060065 9.43 CYP19A1 ESR1
4 cellular response to estrogen stimulus GO:0071391 9.37 ESR1 MDM2
5 xenobiotic transport GO:0042908 9.32 ABCB1 ABCC1
6 metanephric mesenchyme development GO:0072075 9.26 PDGFRB WT1
7 male gonad development GO:0008584 9.26 ESR1 KIT PDGFRB WT1
8 metanephric S-shaped body morphogenesis GO:0072284 9.16 PDGFRB WT1
9 positive regulation of phospholipase C activity GO:0010863 8.8 ESR1 KIT PDGFRB

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 xenobiotic-transporting ATPase activity GO:0008559 8.62 ABCB1 ABCC1

Sources for Uterine Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....